Source link : https://newshealth.biz/health-news/avapritinib-shows-sustained-benefits-in-indolent-systemic-mastocytosis/
The KIT inhibitor avapritinib (Ayvakit) maintained symptom improvement and reduced mast cell burden in patients with indolent systemic mastocytosis for an average of 4 years, according to long-term data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. In this exclusive MedPage Today video, Cem Akin, MD, PhD, of the University […]
The post Avapritinib Shows Sustained Benefits in Indolent Systemic Mastocytosis first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-16 15:28:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8